Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Beijing Biotech
Hangzhou Sumgen Biotech Co., Ltd.
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Caribou Biosciences, Inc.
University College Cork
Cedars-Sinai Medical Center
Baylor College of Medicine
Cancer Research UK
University of Miami
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Brown University
UNC Lineberger Comprehensive Cancer Center
VA Office of Research and Development
Medical University of Gdansk
Centre Hospitalier Régional d'Orléans
CellCentric Ltd.
National Institutes of Health Clinical Center (CC)
Sichuan Baili Pharmaceutical Co., Ltd.
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Cancer Institute (NCI)
Weill Medical College of Cornell University